Cell Type Segment Analysis: T-cells (Largest & Fastest-Growing Segment)

T-cells accounted for the largest and fastest-growing share of the cell therapy technologies market, representing 60.36% share in 2026. Their leading position is closely associated with the expanding development of T-cell-based therapeutic approaches for complex diseases, particularly in areas where engineered immune cells can be used to identify and target abnormal cells. Advances in cell engineering, gene modification, manufacturing workflows, and therapeutic development are strengthening the potential of T-cell platforms across the broader cell therapy landscape. Increasing research activity and continued efforts to develop more precise and scalable cell-based treatments are supporting demand for technologies used in T-cell collection, modification, expansion, characterization, and production. The combination of established therapeutic relevance and ongoing innovation continues to drive strong momentum for T-cell technologies.

End Use Segment Analysis: Biopharmaceutical & Biotechnology Companies (Largest Segment) vs CMOs & CROs (Fastest-Growing Segment)

Biopharmaceutical and biotechnology companies held the largest position in the cell therapy technologies market, accounting for 55.89% share in 2026. These organizations play a central role in discovering, developing, validating, and commercializing cell-based therapies, creating sustained demand for technologies that support cell processing, genetic modification, expansion, quality assessment, and manufacturing. The growing pipeline of cell therapy candidates is encouraging developers to adopt increasingly sophisticated platforms capable of improving consistency and production efficiency. Continued innovation in cell-based therapeutics and the need to translate research programs into scalable manufacturing processes are reinforcing demand from biopharmaceutical and biotechnology organizations.

CMOs and CROs are the fastest-growing end-use segment as cell therapy developers increasingly seek specialized external capabilities to manage complex research, development, testing, and manufacturing requirements. Outsourcing can provide access to specialized expertise, advanced processing infrastructure, and scalable production capabilities without requiring organizations to build every function internally. The technical complexity of cell therapies and the need for controlled, reproducible processes are encouraging greater reliance on specialized service providers. As developers seek to accelerate therapeutic development while managing operational complexity, CMOs and CROs are gaining an increasingly important role in the cell therapy technology ecosystem.